Dashboard Featured
Vertex and Obsidian enter agreement to develop gene-editing treatments
Vertex Pharmaceuticals (VRTX) and Obsidian Therapeutics have entered a strategic research partnership and licensing agreement to discover and develop novel…
Janux Therapeutics raises funding to advance T cell engager treatments
Janux Therapeutics has raised $125m through a series B funding round to advance its pipeline of next-generation T cell engager…
AZ’s proposed acquisition of rare disease-focused Alexion gets US clearance
AstraZeneca’s proposed $39bn acquisition of rare disease therapy company Alexion Pharmaceuticals has passed a US Federal Trade Commission (FTC) review.…
AstraZeneca gets US clearance for proposed Alexion acquisition
The US Federal Trade Commission (FTC) has granted clearance to AstraZeneca for its proposed acquisition of Alexion Pharmaceuticals for approximately…
Thermo Fisher to acquire clinical research company PPD for $17.4bn
Thermo Fisher Scientific (TFS) has announced a definitive agreement to acquire clinical research organisation PPD for $47.50 per share for…